The c-Myc oncoprotein promotes proliferation and apoptosis, such that mutations that disable apoptotic programmes often cooperate with MYC during tumorigenesis. Here we report that two common mutant MYC alleles derived from human Burkitt's lymphoma uncouple proliferation from apoptosis and, as a result, are more effective than wild-type MYC at promoting B cell lymphomagenesis in mice. Mutant MYC proteins retain their ability to stimulate proliferation and activate p53, but are defective at promoting apoptosis due to a failure to induce the BH3-only protein Bim (a member of the B cell lymphoma 2 (Bcl2) family) and effectively inhibit Bcl2. Disruption of apoptosis through enforced expression of Bcl2, or loss of either Bim or p53 function, enables wild-type MYC to produce lymphomas as efficiently as mutant MYC. These data show how parallel apoptotic pathways act together to suppress MYC-induced transformation, and how mutant MYC proteins, by selectively disabling a p53-independent pathway, enable tumour cells to evade p53 action during lymphomagenesis.
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Dang, C. V. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Biol. 19, 1–11 (1999)
Cole, M. D. Activation of the c-myc oncogene. Basic Life Sci. 38, 399–406 (1986)
Spencer, C. A. & Groudine, M. Control of c-myc regulation in normal and neoplastic cells. Adv. Cancer Res. 56, 1–48 (1991)
Dalla-Favera, R. et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. Natl Acad. Sci. USA 79, 7824–7827 (1982)
Davis, M., Malcolm, S. & Rabbitts, T. H. Chromosome translocation can occur on either side of the c-myc oncogene in Burkitt lymphoma cells. Nature 308, 286–288 (1984)
Bhatia, K. et al. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nature Genet. 5, 56–61 (1993)
Albert, T., Urlbauer, B., Kohlhuber, F., Hammersen, B. & Eick, D. Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt's lymphoma cell lines. Oncogene 9, 759–763 (1994)
Clark, H. M. et al. Mutations in the coding region of c-MYC in AIDS-associated and other aggressive lymphomas. Cancer Res. 54, 3383–3386 (1994)
Henriksson, M., Bakardjiev, A., Klein, G. & Luscher, B. Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential. Oncogene 8, 3199–3209 (1993)
Hoang, A. T. et al. A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain. Mol. Cell. Biol. 15, 4031–4042 (1995)
Westaway, D., Payne, G. & Varmus, H. E. Proviral deletions and oncogene base-substitutions in insertionally mutagenized c-myc alleles may contribute to the progression of avian bursal tumors. Proc. Natl Acad. Sci. USA 81, 843–847 (1984)
Salghetti, S. E., Kim, S. Y. & Tansey, W. P. Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO J. 18, 717–726 (1999)
Chang, D. W., Claassen, G. F., Hann, S. R. & Cole, M. D. The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals. Mol. Cell. Biol. 20, 4309–4319 (2000)
Sears, R. C. The life cycle of c-Myc: from synthesis to degradation. Cell Cycle 3, 1133–1137 (2004)
Frykberg, L., Graf, T. & Vennstrom, B. The transforming activity of the chicken c-myc gene can be potentiated by mutations. Oncogene 1, 415–422 (1987)
Yeh, E. et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nature Cell Biol. 6, 308–318 (2004)
Rabbitts, T. H., Hamlyn, P. H. & Baer, R. Altered nucleotide sequences of a translocated c-myc gene in Burkitt lymphoma. Nature 306, 760–765 (1983)
Bemark, M. & Neuberger, M. S. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line. Oncogene 19, 3404–3410 (2000)
Adams, J. M. et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318, 533–538 (1985)
Evan, G. I. et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69, 119–128 (1992)
Lowe, S. W. & Sherr, C. J. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev. 13, 77–83 (2003)
Maclean, K. H., Keller, U. B., Rodriguez-Galindo, C., Nilsson, J. A. & Cleveland, J. L. c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL. Mol. Cell. Biol. 23, 7256–7270 (2003)
Seoane, J., Le, H. V. & Massague, J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419, 729–734 (2002)
Egle, A., Harris, A. W., Bouillet, P. & Cory, S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc. Natl Acad. Sci. USA 101, 6164–6169 (2004)
O'Connor, L. et al. Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J. 17, 384–395 (1998)
Schmitt, C. A. et al. Dissecting p53 tumour suppressor functions in vivo. Cancer Cell 1, 289–298 (2002)
Gaidano, G. et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 88, 5413–5417 (1991)
Bhatia, K. G., Gutierrez, M. I., Huppi, K., Siwarski, D. & Magrath, I. T. The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors. Cancer Res. 52, 4273–4276 (1992)
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593–602 (1997)
Yu, D. & Thomas-Tikhonenko, A. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. Oncogene 21, 1922–1927 (2002)
We thank M. S. Jiao, C. Rosenthal, M. Yang, S. Ray, C. Yang and I. Linkov for technical assistance and J. Zilfou, R. Dickins, E. Cepero, M. Spector, J. Fridman and other members of the Lowe laboratory for advice and/or critical reading of the manuscript. We also thank A. Hunt and G. Evan for helpful advice, and T. Mak and A. Strasser for mice. This work was supported by a postdoctoral fellowship from the Helen Hay Whitney Foundation (M.T.H.), an NCI postdoctoral training grant (A.B.), a program project grant from the National Cancer Institute (W.P.T and S.W.L.) and a grant from the Irving Hansen Memorial Foundation (W.P.T). W.P.T. is a Leukemia and Lymphoma Society Scholar and S.W.L. is an AACR-NCRF Research Professor.
Reprints and permissions information is available at npg.nature.com/reprintsandpermissions. The authors declare no competing financial interests.
This figure shows a diagram of the adoptive transfer strategy, as well as diagrams of the retroviral vectors used. (Canvas image, 248KB) (PDF 90 kb)
This figure shows immunohistochemistry staining of lymphoma cells. It also shows GFP histograms of cells before and after stem cell reconstitution. (Canvas image, 1.3MB) (PDF 237 kb)
This figure shows western blot analysis of FL5.12 pre-B cells. It also shows PCR analysis of DJ recombination to assess tumor clonality. (Canvas image, 1.4MB) (PDF 702 kb)
A table showing the p53 and MYC status of 31 Burkitt lymphomas. (MS Word file, 12KB) (RTF 8 kb)
A file containing figure legends for the Supplementary Figures. (MS Word file, 8KB) (RTF 6 kb)
About this article
Cite this article
Hemann, M., Bric, A., Teruya-Feldstein, J. et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436, 807–811 (2005). https://doi.org/10.1038/nature03845
Annual Review of Pharmacology and Toxicology (2021)
PLOS ONE (2021)
International Journal of Molecular Sciences (2021)
The Impact of Epstein-Barr Virus Infection on Epigenetic Regulation of Host Cell Gene Expression in Epithelial and Lymphocytic Malignancies
Frontiers in Oncology (2021)